1
|
Jonsson H, Andersson A, Mao Z, Nyström L. Age-specific differences in tumour characteristics between screen-detected and non-screen-detected breast cancers in women aged 40-74 at diagnosis in Sweden from 2008 to 2017. J Med Screen 2024:9691413241237616. [PMID: 38454634 DOI: 10.1177/09691413241237616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2024]
Abstract
OBJECTIVE To analyze differences between screen-detected and non-screen-detected invasive breast cancers by tumour characteristics and age at diagnosis in the nationwide population-based mammography screening program in Sweden. METHODS Data were retrieved from the National Quality Register for Breast Cancer for 2008-2017. Logistic regression analysis was used to estimate the likelihood for a tumour to be screen-detected by tumour characteristics and age group at diagnosis. RESULTS In total there were 51,429 invasive breast cancers in the target age group for mammography screening of 40-74 years. Likelihood of screen detection decreased with larger tumour size, lymph node metastases, higher histological grade and distant metastasis. Odds ratios (ORs) for negative oestrogen (ER) and progesterone (PgR) were 0.41 and 0.57; for positive HER2, 0.62; for Ki-67 high versus low, 0.49. Molecular sub-types had OR of 0.56, 0.40 and 0.28, respectively, for luminal B-like, HER2-positive and triple negative versus luminal A-like. Adjusting for tumour size (T), lymph node status (N), age, year and county at diagnosis slightly elevated the ORs. Statistically significant interactions between tumour characteristics and age were found (p < 0.05) except for ER and PgR. The age group 40-49 deviated most from the other age groups. CONCLUSIONS Our study demonstrates that screen-detected invasive breast cancers had more favourable tumour characteristics than non-screen-detected after adjusting for age, year and county of diagnosis, and even after adjusting for T and N. The trend towards favourable tumour characteristics was less pronounced in the 40-49 age group compared to the other age groups, except for ER and PgR.
Collapse
Affiliation(s)
- Håkan Jonsson
- Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
- Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden
| | - Anne Andersson
- Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
| | - Zheng Mao
- Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
| | - Lennarth Nyström
- Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden
| |
Collapse
|
2
|
Jarm K, Kadivec M, Šval C, Hertl K, Primic Žakelj M, Dean PB, von Karsa L, Žgajnar J, Gazić B, Kutnar V, Zdešar U, Kurir Borovčić M, Zadnik V, Josipović I, Krajc M. Quality assured implementation of the Slovenian breast cancer screening programme. PLoS One 2021; 16:e0258343. [PMID: 34624045 PMCID: PMC8500434 DOI: 10.1371/journal.pone.0258343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 09/26/2021] [Indexed: 12/01/2022] Open
Abstract
SETTING The organised, population-based breast cancer screening programme in Slovenia began providing biennial mammography screening for women aged 50-69 in 2008. The programme has taken a comprehensive approach to quality assurance as recommended by the European guidelines for quality assurance in breast cancer screening and diagnosis (4th edition), including centralized assessment, training and supervision, and proactive monitoring of performance indicators. This report describes the progress of implementation and rollout from 2003 through 2019. METHODS The screening protocol and key quality assurance procedures initiated during the planning from 2003 and rollout from 2008 of the screening programme, including training of the professional staff, are described. The organisational structure, gradual geographical rollout, and coverage by invitation and examination are presented. RESULTS The nationwide programme was up and running in all screening regions by the end of 2017, at which time the nationwide coverage by invitation and examination had reached 70% and 50%, respectively. Nationwide rollout of the population-based programme was complete by the end of 2019. By this time, coverage by invitation and examination had reached 98% and 76%, respectively. The participation rates consistently exceeded 70% from 2014 to 2019. CONCLUSIONS The successful implementation of the screening programme can be attributed to an independent central management, external guidance, and strict adherence to quality assurance procedures, all of which contributed to increasing governmental and popular support. The benefits of quality assurance have influenced all aspects of breast care and have provided a successful model for multidisciplinary management of other diseases.
Collapse
Affiliation(s)
- Katja Jarm
- Institute of Oncology Ljubljana, Ljubljana, Slovenia
- University of Ljubljana, Ljubljana, Slovenia
| | | | - Cveto Šval
- Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | | | | | - Peter B. Dean
- Department of Diagnostic Radiology, University of Turku, Turku, Finland
- Formerly at the International Agency for Research on Cancer, Lyon, France
| | - Lawrence von Karsa
- Formerly at the International Agency for Research on Cancer, Lyon, France
| | - Janez Žgajnar
- Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | - Barbara Gazić
- Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | | | - Urban Zdešar
- Institute of Occupational Safety, Ljubljana, Slovenia
| | | | - Vesna Zadnik
- Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | | | - Mateja Krajc
- Institute of Oncology Ljubljana, Ljubljana, Slovenia
- University of Ljubljana, Ljubljana, Slovenia
| |
Collapse
|
3
|
Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark. Breast Cancer Res Treat 2020; 184:891-899. [PMID: 32862304 PMCID: PMC7655583 DOI: 10.1007/s10549-020-05896-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Accepted: 08/18/2020] [Indexed: 11/04/2022]
Abstract
Introduction Service breast cancer screening is difficult to evaluate because there is no unscreened control group. Due to a natural experiment, where 20% of women were offered screening in two regions up to 17 years before other women, Denmark is in a unique position. We utilized this opportunity to assess outcome of service screening. Materials and methods Screening was offered in Copenhagen from 1991 and Funen from 1993 to women aged 50–69 years. We used difference-in-differences methodology with a study group offered screening; a historical control group; a regional control group; and a regional–historical control group, comparing breast cancer mortality and incidence, including ductal carcinoma in situ, between study and historical control group adjusted for changes in other regions, and calculating ratios of rate ratios (RRR) with 95% confidence intervals (CI). Data came from Central Population Register; mammography screening databases; Cause of Death Register; and Danish Cancer Register. Results For breast cancer mortality, the study group accumulated 1,551,465 person-years and 911 deaths. Long-term breast cancer mortality in Copenhagen was 20% below expected in absence of screening; RRR 0.80 (95% CI 0.71–0.90), and in Funen 22% below; RRR 0.78 (95% CI 0.68–0.89). Combined, cumulative breast cancer incidence in women followed 8+ years post-screening was 2.3% above expected in absence of screening; RRR 1.023 (95% CI 0.97–1.08). Discussion Benefit-to-harm ratio of the two Danish screening programs was 2.6 saved breast cancer deaths per overdiagnosed case. Screening can affect only breast cancers diagnosed in screening age. Due to high breast cancer incidence after age 70, only one-third of breast cancer deaths after age 50 could potentially be affected by screening. Increasing upper age limit could be considered, but might affect benefit-to-harm ratio negatively.
Collapse
|
4
|
Moseholm E, Lindhardt BØ. Patient characteristics and cancer prevalence in the Danish cancer patient pathway for patients with serious non-specific symptoms and signs of cancer-A nationwide, population-based cohort study. Cancer Epidemiol 2017; 50:166-172. [PMID: 28807680 DOI: 10.1016/j.canep.2017.08.003] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Revised: 07/31/2017] [Accepted: 08/03/2017] [Indexed: 11/15/2022]
Abstract
BACKGROUND A new cancer patient pathway for patients presenting with non-specific signs and symptoms (NSSC-CPP) was implemented nationally in Denmark in 2012. This study aims to describe, on a national level, the characteristics of patients referred to the Danish NSSC-CPP, and to estimate the prevalence and distribution of cancers and other diagnosis in this population. METHODS A population-based cohort study using the Danish national registries, including all patients who completed a diagnostic course through the NSSC-CPP between 2012 and 2015. Cancer prevalence is presented as the percentage of included patients who were diagnosed with cancer after completing a NSSC-CPP diagnostic course. Associations between patient characteristics and cancer diagnosis were estimated in a multivariate logistic regression model. RESULTS The mean age of the 23,934 patients included in the analysis was 64.6 years and 47% where male. In total, 11% of all patients received a cancer diagnosis after completing a diagnostic course in the NSSC-CPP; the most common types were breast cancer (18%) hematopoietic and lymphoid tissue cancer (15%), and malignant melanoma (12%). The most common non-cancer diagnosis was non-specific symptoms/observation (54%). Fifty-five patients were diagnosed with cancer within six months following a non-cancer diagnosis in the NSSC-CPP. CONCLUSIONS The prevalence of cancer in the NSSC-CPP was 11%. The most common cancer diagnosis was breast cancer, hematopoietic and lymphoid cancer and malignant melanoma. A small proportion of patients receiving a non-cancer diagnosis in the NSSC-CPP were diagnosed with cancer in the six months following their NSSC-CPP course.
Collapse
Affiliation(s)
- E Moseholm
- Department of Pulmonary and Infectious Diseases, University Hospital of Copenhagen, Nordsjælland Dyrehavevej 29, DK-3400 Hillerød, Denmark.
| | - B Ø Lindhardt
- Department of Infectious Diseases, University Hospital of Copenhagen, Hvidovre, Kettegård Alle 30, Department 144, DK-2650 Hvidovre, Denmark.
| |
Collapse
|
5
|
Lynge E, Beau AB, Christiansen P, von Euler-Chelpin M, Kroman N, Njor S, Vejborg I. Overdiagnosis in breast cancer screening: The impact of study design and calculations. Eur J Cancer 2017; 80:26-29. [PMID: 28535494 DOI: 10.1016/j.ejca.2017.04.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Revised: 04/05/2017] [Accepted: 04/17/2017] [Indexed: 10/19/2022]
Abstract
Overdiagnosis in breast cancer screening is an important issue. A recent study from Denmark concluded that one in three breast cancers diagnosed in screening areas in women aged 50-69 years were overdiagnosed. The purpose of this short communication was to disentangle the study's methodology in order to evaluate the soundness of this conclusion. We found that both the use of absolute differences as opposed to ratios; the sole focus on non-advanced tumours and the crude allocation of tumours and person-years by screening history for women aged 70-84 years, all contributed to the very high estimate of overdiagnosis. Screening affects cohorts of screened women. Danish registers allow very accurate mapping of the fate of every woman. We should be past the phase where studies of overdiagnosis are based on the fixed age groups from routine statistics.
Collapse
Affiliation(s)
- Elsebeth Lynge
- Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, DK 1014 København K, Denmark.
| | - Anna-Belle Beau
- Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, DK 1014 København K, Denmark
| | - Peer Christiansen
- Plastic and Breast Surgery, Breast Surgery Unit, Aarhus University Hospital/Randers Regional Hospital, Norrebrogade 44, DK 8000 Aarhus C, Denmark
| | - My von Euler-Chelpin
- Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, DK 1014 København K, Denmark
| | - Niels Kroman
- Copenhagen University Hospital, Rigshospitalet, Copenhagen, Blegdamsvej 9, DK 2100 København K, Denmark
| | - Sisse Njor
- Department of Clinical Epidemiology, Aarhus University, Olof Palmes Allé 43-45, DK 8200 Aarhus N, Denmark
| | - Ilse Vejborg
- Copenhagen University Hospital, Rigshospitalet, Copenhagen, Blegdamsvej 9, DK 2100 København K, Denmark
| |
Collapse
|
6
|
Tian S, Bertelsmann K, Yu L, Sun S. DNA Methylation Heterogeneity Patterns in Breast Cancer Cell Lines. Cancer Inform 2016; 15:1-9. [PMID: 27688708 PMCID: PMC5032785 DOI: 10.4137/cin.s40300] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Revised: 08/07/2016] [Accepted: 08/13/2016] [Indexed: 12/25/2022] Open
Abstract
Heterogeneous DNA methylation patterns are linked to tumor growth. In order to study DNA methylation heterogeneity patterns for breast cancer cell lines, we comparatively study four metrics: variance, I2 statistic, entropy, and methylation state. Using the categorical metric methylation state, we select the two most heterogeneous states to identify genes that directly affect tumor suppressor genes and high- or moderate-risk breast cancer genes. Utilizing the Gene Set Enrichment Analysis software and the ConsensusPath Database visualization tool, we generate integrated gene networks to study biological relations of heterogeneous genes. This analysis has allowed us to contribute 19 potential breast cancer biomarker genes to cancer databases by locating “hub genes” – heterogeneous genes of significant biological interactions, selected from numerous cancer modules. We have discovered a considerable relationship between these hub genes and heterogeneously methylated oncogenes. Our results have many implications for further heterogeneity analyses of methylation patterns and early detection of breast cancer susceptibility.
Collapse
Affiliation(s)
- Sunny Tian
- Massachusetts Institute of Technology, Cambridge, MA, USA
| | | | - Linda Yu
- St. John's School, Houston, TX, USA
| | - Shuying Sun
- Department of Mathematics, Texas State University, San Marcos, TX, USA
| |
Collapse
|
7
|
Jacobsen KK, von Euler Chelpin M, Vejborg I, Lynge E. Impact of invitation schemes on breast cancer screening coverage: A cohort study from Copenhagen, Denmark. J Med Screen 2016; 24:20-26. [PMID: 27206815 PMCID: PMC5414897 DOI: 10.1177/0969141316641982] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background The purpose of mammography screening is to decrease breast cancer mortality. To achieve this a high coverage by examination is needed. Within an organized screening programme, we examined the impact of changes in the invitation schedule on the interplay between coverage and participation. Method We studied nine cohorts aged 50-51 when first targeted by mammography screening in Copenhagen, Denmark. Population data were retrieved from the Danish Civil Registration System; invitation and attendance data from the screening programme database. Data were linked using unique personal identification numbers. Coverage by invitation was defined as (number of invited women/number of targeted women), coverage by examination as (number of screened women/number of targeted women), and participation rate as (number of screened women/number of invited women). Results Coverage by invitation was close to or above 95% for all newly recruited cohorts. In subsequent invitation rounds, both technical errors and changes in the invitation scheme affected the coverage by invitation. Coverage by examination at first invitation was 72.5% for the first cohort, but dropped to 64.2% for the latest cohort. Furthermore, coverage by examination dropped by increasing invitation number and with omission of re-invitation of previous non-attenders. Participation rate closely reflected changes in the invitation scheme. Conclusion Changes in the invitation schemes influenced coverage by invitation, coverage by examination, and participation rate. We observed a considerable gap between coverage by examination and participation rate, strongly indicating that the latter cannot without reservations, be taken as an indicator of the first.
Collapse
Affiliation(s)
- Katja Kemp Jacobsen
- 1 Department of Public Health, University of Copenhagen, Copenhagen, Denmark
| | | | - Ilse Vejborg
- 2 Department of Radiology, Center of Diagnostic Imaging, Copenhagen University Hospital, Copenhagen, Denmark
| | - Elsebeth Lynge
- 1 Department of Public Health, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
8
|
Kemp Jacobsen K, O'Meara ES, Key D, S M Buist D, Kerlikowske K, Vejborg I, Sprague BL, Lynge E, von Euler-Chelpin M. Comparing sensitivity and specificity of screening mammography in the United States and Denmark. Int J Cancer 2015; 137:2198-207. [PMID: 25944711 DOI: 10.1002/ijc.29593] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Revised: 04/20/2015] [Accepted: 04/23/2015] [Indexed: 11/06/2022]
Abstract
Delivery of screening mammography differs substantially between the United States (US) and Denmark. We evaluated whether there are differences in screening sensitivity and specificity. We included screens from women screened at age 50-69 years during 1996-2008/2009 in the US Breast Cancer Surveillance Consortium (BCSC) (n = 2,872,791), and from two population-based mammography screening programs in Denmark (Copenhagen, n = 148,156 and Funen, n = 275,553). Women were followed-up for 1 year. For initial screens, recall rate was significantly higher in BCSC (17.6%) than in Copenhagen (4.3%) and Funen (3.1%). Sensitivity was fairly similar in BCSC (91.8%) and Copenhagen (90.5%) and Funen (92.5%). At subsequent screens, recall rates were 8.8%, 1.8% and 1.4% in BCSC, Copenhagen and Funen, respectively. The BCSC sensitivity (82.3%) was lower compared with that in Copenhagen (88.9%) and Funen (86.9%), but when stratified by time since last screen, the sensitivity was similar. For both initial and subsequent screenings, the specificity of screening in BCSC (83.2% and 91.6%) was significantly lower than that in Copenhagen (96.6% and 98.8%) and Funen (97.9% and 99.2%). By taking time since last screen into account, it was found that American and Danish women had the same probability of having their asymptomatic cancers detected at screening. However, the majority of women free of asymptomatic cancers experienced more harms in terms of false-positive findings in the US than in Denmark.
Collapse
Affiliation(s)
- Katja Kemp Jacobsen
- Department of Public Health, University of Copenhagen, Copenhagen K, Denmark
| | | | - Dustin Key
- Group Health Research Institute, Seattle, WA, USA
| | | | - Karla Kerlikowske
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.,General Internal Medicine Section, Department of Veterans Affairs, University of California, San Francisco, CA, USA
| | - Ilse Vejborg
- Center of Diagnostic Imaging, Copenhagen University Hospital, Rigshospitalet, Denmark
| | - Brian L Sprague
- Department of Surgery, University of Vermont, Burlington, VT, USA
| | - Elsebeth Lynge
- Department of Public Health, University of Copenhagen, Copenhagen K, Denmark
| | | |
Collapse
|
9
|
Hellmann SS, Njor SH, Lynge E, von Euler-Chelpin M, Olsen A, Tjønneland A, Vejborg I, Andersen ZJ. Body mass index and participation in organized mammographic screening: a prospective cohort study. BMC Cancer 2015; 15:294. [PMID: 25880028 PMCID: PMC4404005 DOI: 10.1186/s12885-015-1296-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2014] [Accepted: 03/31/2015] [Indexed: 11/10/2022] Open
Abstract
Background Breast cancer is the leading cancer among women, and early diagnosis is essential for future prognosis. Evidence from mainly cross-sectional US studies with self-reported exposure and outcome found positive association of body mass index (BMI) with non-participation in mammographic screening, but hardly addressed the influence of potential effect-modifiers. We studied the association between objective measures of BMI and participation in mammographic screening in a Danish prospective cohort, and explored the influence of menopausal status, hormone therapy (HT), previous screening participation, and morbidities on this relationship. Methods A total of 5,134 women from the Diet, Cancer, and Health cohort who were invited to population based mammographic screening in Copenhagen were included in analysis. Women were 50–64 years old at inclusion (1993–97) when their height and weight were measured and covariates collected via questionnaire. Odds ratios (OR) and 95% confidence intervals (CI) for the association between BMI and mammographic screening participation were estimated by logistic regression, adjusted for other breast cancer risk factors and morbidities. Effect modification was evaluated by an interaction term and tested by Wald test. Results Underweight (BMI < 18.5 kg/m2, OR: 95% CI; 2.24: 1.27-3.96) and obese women of class II (BMI 35–40 kg/m2, 1.54: 0.99-2.39) and III (BMI ≥ 40 kg/m2, 1.81: 0.95-3.44) had significantly higher odds of non-participation than women with normal weight. This association was limited to postmenopausal women (Wald test p = 0.08), with enhanced non-participation in underweight (2.83: 1.52-5.27) and obese women of class II and III (1.84: 1.15-2.95; 2.47: 1.20-5.06) as compared to normal weight postmenopausal women. There was no effect modification by HT, previous screening participation, or morbidities, besides suggestive evidence of enhanced non-participation in diabetic overweight and obese women. Conclusions Underweight and very obese postmenopausal women were significantly less likely to participate in mammographic screening than women with normal weight, while BMI was not related to screening in premenopausal women. Effect of BMI on mammographic screening participation was not significantly modified by HT, previous screening participation, or morbidities.
Collapse
Affiliation(s)
- Sophie Sell Hellmann
- Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1014, Copenhagen, Denmark.
| | - Sisse Helle Njor
- Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1014, Copenhagen, Denmark.
| | - Elsebeth Lynge
- Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1014, Copenhagen, Denmark.
| | - My von Euler-Chelpin
- Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1014, Copenhagen, Denmark.
| | - Anja Olsen
- Danish Cancer Society, Institute of Cancer Epidemiology, Strandboulevarden 49, 2100, Copenhagen, Denmark.
| | - Anne Tjønneland
- Danish Cancer Society, Institute of Cancer Epidemiology, Strandboulevarden 49, 2100, Copenhagen, Denmark.
| | - Ilse Vejborg
- Diagnostic Imaging Centre, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.
| | - Zorana Jovanovic Andersen
- Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1014, Copenhagen, Denmark.
| |
Collapse
|
10
|
Andersen SB, Törnberg S, Kilpeläinen S, Lynge E, Njor SH, Von Euler-Chelpin M. Measuring the burden of interval cancers in long-standing screening mammography programmes. J Med Screen 2015; 22:83-92. [DOI: 10.1177/0969141314560386] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Accepted: 10/29/2014] [Indexed: 11/16/2022]
Abstract
Objectives Mammography screening programme sensitivity is evaluated by comparing the interval cancer rate (ICR) with the expected breast cancer incidence without screening, ie. the proportional interval cancer rate (PICR). The PICR is usually found by extrapolating pre-screening incidence rates, whereas ICR is calculated from data available in the screening programmes. As there is no consensus regarding estimation of background incidence, we seek to validate the ICR measure against the PICR. Methods Screening data from the three mammography screening programmes of Stockholm, Copenhagen, and Funen in the period 1989-2011 provided data to calculate the ICR. The most commonly described methods of extrapolating pre-screening incidence rates to calculate the PICR were illustrated and PICRs were calculated by year and programme using these different methods and compared with the ICRs. Results PICRs varied greatly, reaching a difference of 32–34% in Stockholm, 79% in Copenhagen, and 100–106% in Funen between the highest and the lowest value, depending on which method was applied. PICRs exhibited large variations yearly and from programme to programme. ICRs did not vary to the same extent, ranging on average from 0.100 to 0.136 in the first 12-months and between 0.201 and 0.225 in the last 12-months of the two-year period after a negative screen across the three programmes. Conclusion The value of the PICR is hugely influenced by which method is applied, whereas the ICR is calculated purely on data available within programmes. We find that the PICR, the establishing indicator for sensitivity, could preferably be replaced by the ICR.
Collapse
Affiliation(s)
| | | | | | - Elsebeth Lynge
- Department of Public Health, University of Copenhagen, Denmark
| | | | | |
Collapse
|
11
|
Altobelli E, Lattanzi A. Breast cancer in European Union: an update of screening programmes as of March 2014 (review). Int J Oncol 2014; 45:1785-92. [PMID: 25174328 PMCID: PMC4203333 DOI: 10.3892/ijo.2014.2632] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2014] [Accepted: 06/26/2014] [Indexed: 12/11/2022] Open
Abstract
Breast cancer, a major cause of female morbidity and mortality, is a global health problem; 2008 data show an incidence of ~450,000 new cases and 140,000 deaths (mean incidence rate 70.7 and mortality rate 16.7, world age-standardized rate per 100,000 women) in European Union Member States. Incidence rates in Western Europe are among the highest in the world. We review the situation of BC screening programmes in European Union. Up to date information on active BC screening programmes was obtained by reviewing the literature and searching national health ministries and cancer service websites. Although BC screening programmes are in place in nearly all European Union countries there are still considerable differences in target population coverage and age and in the techniques deployed. Screening is a mainstay of early BC detection whose main weakness is the rate of participation of the target population. National policies and healthcare planning should aim at maximizing participation in controlled organized screening programmes by identifying and lowering any barriers to adhesion, also with a view to reducing healthcare costs.
Collapse
Affiliation(s)
- E Altobelli
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - A Lattanzi
- Epidemiologic and Social Marketing Unit, AUSL 4 Teramo, Italy
| |
Collapse
|
12
|
José Bento M, Gonçalves G, Aguiar A, Antunes L, Veloso V, Rodrigues V. Clinicopathological differences between interval and screen-detected breast cancers diagnosed within a screening programme in Northern Portugal. J Med Screen 2014; 21:104-9. [DOI: 10.1177/0969141314534406] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Objective To evaluate clinicopathological differences between screen-detected (SD) and interval (IC) breast cancers diagnosed in women enrolled in an organized breast screening programme in 2000--2007. Setting Breast Cancer Screening Programme of the north region of Portugal. Methods Using data from the screening programme and from the population-based North Region Cancer Registry, SD and IC were identified. Information on screening history, age, date of diagnosis, tumour size, histological type and grade, lymph node status, tumour stage, biomarkers, and treatment was obtained from the cancer registry and from clinical and pathological reports. Association between mode of detection and these clinicopathological characteristics was estimated by unconditional logistic regression. Results A total of 442 SD and 112 IC were identified in women aged 50--69. Compared with SD, IC were diagnosed in younger women (60.0 ± 5.8 years and 58.4 ± 6.0 years, respectively), were larger (tumour size >20 mm: 60.2% versus 25.1%), lobular (6.3% versus 16.1%), with a higher differentiation grade (grade 3: 17.7% versus 38.9%), had more lymph node metastases, more advanced stage, and oestrogen receptor (ER) negative (12.9% versus 29.0%) and progesterone negative, and HER2 positive. After multivariable analysis, compared with SD, IC were more likely to be larger than 20 mm, lobular, of grade 3 and negative for ER. Conclusion Our results are consistent with other studies. IC’s have a more aggressive biology than SDs. Our findings did not show any unexpected pattern requiring changes to our screening procedures, but continuous identification and characterization of IC is advisable.
Collapse
Affiliation(s)
- Maria José Bento
- Institute of Biomedical Sciences Abel Salazar, University of Porto, and Epidemiology Unit, Portuguese Oncology Institute, Porto, Portugal
| | - Guilherme Gonçalves
- Institute of Biomedical Sciences Abel Salazar, University of Porto, Portugal
| | - Ana Aguiar
- Portuguese Cancer League – North Branch, Porto, Portugal
| | - Luis Antunes
- Institute of Biomedical Sciences Abel Salazar, University of Porto, Portugal
| | - Vitor Veloso
- Portuguese Cancer League – North Branch, Porto, Portugal
| | - Vítor Rodrigues
- Faculty of Medicine, University of Coimbra, and Portuguese Cancer League – Centre Branch, Coimbra, Portugal
| |
Collapse
|
13
|
Christiansen P, Vejborg I, Kroman N, Holten I, Garne JP, Vedsted P, Møller S, Lynge E. Position paper: breast cancer screening, diagnosis, and treatment in Denmark. Acta Oncol 2014; 53:433-44. [PMID: 24495043 DOI: 10.3109/0284186x.2013.874573] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
BACKGROUND During the last decades the diagnosis, treatment, and prognosis of breast cancer have changed and improved in Denmark. The first mammography screening programme started in 1991. However, for many years only about 20% of Danish women aged 50-69 were offered screening. The national roll-out of screening took place in 2008-2010. MATERIAL AND METHODS Based on published Danish data, this overview describes the status of diagnosis and treatment, and the screening programme. For further evaluating the potential overdiagnosis and overtreatment, additional Danish Breast Cancer Cooperative Group (DBCG) data are included. RESULTS AND CONCLUSION Using incidence-based mortality method, reduction in breast cancer mortality was estimated to be 25% in the target group of women after 10 years of screening in Copenhagen; an outcome comparable to that of randomised controlled trials. A recent Danish study has indicated overdiagnosis to be around 4%. Others have estimated overdiagnosis to be 33%. National DBCG data showed that the rude breast cancer incidence increased during the period 1990-2011 from 126 to 206 per 100 000. The incidence was almost constant for women younger than 50 years. In regions not offering screening, the incidence increased with 3% per year for women aged 50-69 years with similar trends for small and large tumours. After introduction of screening the increase in the age group 50-69 years was confined to small tumours ≤ 20 mm, and most pronounced for node negative patients. From the 1990s, the use of breast conserving surgery has increased from around 25% to 69% in 2010. Screening has not increased the number of mastectomies. Breast cancer treatment in Denmark is evidence based and in agreement with international recommendations. After the introduction of mammography screening the absolute number of patients with a more advanced stage at diagnosis and the absolute number of patients undergoing mastectomy have decreased.
Collapse
Affiliation(s)
- Peer Christiansen
- Breast and Endocrine Section, Department of Surgery P, Aarhus University Hospital,
Aarhus, Denmark
| | - Ilse Vejborg
- Department of Radiology, Copenhagen University Hospital,
Copenhagen, Denmark
| | - Niels Kroman
- Department of Breast Surgery, Copenhagen University Hospital,
Rigshospitalet, Copenhagen, Denmark
| | - Iben Holten
- Department of Prevention and Documentation, Danish Cancer Society,
Copenhagen, Denmark
| | - Jens Peter Garne
- Department of Breast Surgery, Aalborg University Hospital,
Aalborg, Denmark
| | - Peter Vedsted
- The Research Unit for General Practice, Danish Research Centre for Cancer Diagnosis in Primary Care (CaP), School of Public Health, Aarhus University,
Aarhus, Denmark
| | - Susanne Møller
- DBCG Data Center, Copenhagen University Hospital,
Rigshospitalet, Copenhagen, Denmark
| | - Elsebeth Lynge
- Department of Public Health, University of Copenhagen,
Copenhagen, Denmark
| |
Collapse
|